Last reviewed · How we verify
NCT07122492: FoRtitude
A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)
NA trial testing FoRtitude 2.0 in Breast Cancer Survivor in 800 participants. Not yet recruiting.
1 September 2028
Quick facts
| Lead sponsor | Eastern Cooperative Oncology Group |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 800 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2028 |
| Estimated completion | 1 September 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- FoRtitude 2.0
- Attention Control
Conditions studied
- Breast Cancer Survivor — all drugs for Breast Cancer Survivor →
- Fear of Cancer Recurrence — all drugs for Fear of Cancer Recurrence →
Sponsor
Eastern Cooperative Oncology Group
Who can join
18 and older, female only, with Breast Cancer Survivor or Fear of Cancer Recurrence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are: Can the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors? Participants will: Answer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community. Be asked to fill out questionnaires 5 times for up to 18 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07122492
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Survivor
Currently open trials in the same condition.
- NCT07015944 — Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan · NA · recruiting
- NCT07083518 — Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors · NA · active not recruiting
- NCT06938555 — The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors · NA · recruiting
- NCT06671730 — Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast · NA · recruiting
Other Eastern Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
- NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
- NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
- NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting
- NCT06724237 — Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With P · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07122492 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
- Last refreshed: 14 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07122492.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing